Evolus Inc (NASDAQ:EOLS) Short Interest Update

Share on StockTwits

Evolus Inc (NASDAQ:EOLS) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 5,700,000 shares, an increase of 11.8% from the December 15th total of 5,100,000 shares. Based on an average trading volume of 553,500 shares, the short-interest ratio is presently 10.3 days. Approximately 25.6% of the shares of the stock are sold short.

Shares of EOLS traded up $0.28 during mid-day trading on Thursday, hitting $11.12. The company’s stock had a trading volume of 9,188 shares, compared to its average volume of 675,165. The company’s 50-day moving average is $12.19 and its 200-day moving average is $14.93. Evolus has a 52-week low of $10.31 and a 52-week high of $30.25. The firm has a market capitalization of $366.67 million, a price-to-earnings ratio of -6.99 and a beta of 4.24. The company has a current ratio of 3.66, a quick ratio of 3.28 and a debt-to-equity ratio of 4.53.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.55. The business had revenue of $13.17 million during the quarter, compared to analysts’ expectations of $5.18 million. As a group, sell-side analysts predict that Evolus will post -3.75 earnings per share for the current fiscal year.

In other Evolus news, insider Rui Avelar sold 39,442 shares of Evolus stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $10.71, for a total value of $422,423.82. Following the sale, the insider now directly owns 70,802 shares in the company, valued at approximately $758,289.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 3.90% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp lifted its position in shares of Evolus by 21.6% in the 3rd quarter. State Street Corp now owns 230,987 shares of the company’s stock worth $3,608,000 after purchasing an additional 41,046 shares during the period. Point72 Asset Management L.P. bought a new position in shares of Evolus during the 2nd quarter worth approximately $4,167,000. Rhumbline Advisers raised its stake in shares of Evolus by 15.2% during the 3rd quarter. Rhumbline Advisers now owns 14,797 shares of the company’s stock worth $231,000 after acquiring an additional 1,953 shares in the last quarter. Millennium Management LLC raised its stake in shares of Evolus by 36.7% during the 3rd quarter. Millennium Management LLC now owns 170,072 shares of the company’s stock worth $2,656,000 after acquiring an additional 45,653 shares in the last quarter. Finally, HighTower Advisors LLC bought a new position in shares of Evolus during the 2nd quarter worth approximately $175,000. 16.94% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Evolus from a “sell” rating to a “hold” rating in a report on Tuesday, October 15th. Leerink Swann started coverage on shares of Evolus in a report on Tuesday, November 26th. They issued an “outperform” rating and a $25.00 target price on the stock. Svb Leerink started coverage on shares of Evolus in a report on Tuesday, November 26th. They issued an “outperform” rating and a $25.00 target price on the stock. ValuEngine upgraded shares of Evolus from a “hold” rating to a “buy” rating in a report on Monday, November 4th. Finally, HC Wainwright reissued a “buy” rating on shares of Evolus in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $26.36.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Article: How To Calculate Debt-to-Equity Ratio

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.